Related Experiment Video
Updated: Jun 27, 2026
Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection
Published on: May 9, 2022
Tunable Technologies for the Glioma Tumor Microenvironment: A Comprehensive Review on Bench-to-Bedside Neurosurgical
Eshita Sharma1, Julieta Serobyan1, Numa Rajab2
1David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
Abstract:
Gliomas remain among the most treatment-resistant malignancies of the central nervous system. Glioblastoma (GBM), the most aggressive adult-type diffuse glioma, is associated with persistently poor survival despite maximal safe resection followed by chemoradiation. Gliomas do not grow in isolation. Work over the past twenty years has dismantled the older tumor-centric view of glioma biology, replacing it with a model in which malignant cells operate within a tumor microenvironment (TME) composed of immune, vascular, stromal, and neural elements that together govern disease behavior. What makes the glioma TME so difficult to treat is not just its composition of immune cells, vasculature, stroma, and neurons, but the fact that these elements are arranged unevenly across the tumor. Different regions harbor different cellular mixtures and signaling environments, and, as a result, different vulnerabilities to therapy. Cytoreduction has not lost its importance, far from it. However, the same surgical window now also serves a different purpose; it lets the surgeon see which tissue is biologically dangerous rather than just visually abnormal, locate the true edge of infiltration, and get therapeutics past a blood-brain barrier (BBB) that has historically locked them out of the brain. This review examines two technology domains, including: (1) optical theranostics (5-aminolevulinic acid fluorescence-guided surgery, fluorescein-guided visualization, Raman spectroscopy, and stimulated Raman histology); and (2) blood-brain barrier disrupting technologies. The direction they collectively point toward is a version of glioma surgery that is guided less by anatomy and more by the biology of the tumor itself.
Insights
New surgical technologies for brain gliomas focus on tumor biology, not just visual appearance. These advancements aim to improve treatment by targeting the complex tumor microenvironment and overcoming the blood-brain barrier.
Area of Science:
- Neuro-oncology
- Surgical Innovation
- Biomedical Engineering
Background:
- Gliomas, particularly glioblastoma (GBM), are highly treatment-resistant central nervous system malignancies.
- The tumor microenvironment (TME), comprising immune, vascular, stromal, and neural elements, significantly influences glioma behavior.
- Tumor heterogeneity within the TME presents challenges for effective therapy.
Purpose of the Study:
- To review emerging technologies for glioma surgery.
- To highlight a shift towards biology-guided surgical approaches.
- To discuss methods for overcoming the blood-brain barrier (BBB).
Main Methods:
- Examination of optical theranostics, including 5-aminolevulinic acid fluorescence-guided surgery, fluorescein-guided visualization, Raman spectroscopy, and stimulated Raman histology.
- Review of blood-brain barrier (BBB) disrupting technologies.
- Analysis of how these technologies enable biology-guided glioma surgery.
Main Results:
- Optical theranostics provide real-time biological information during surgery.
- BBB disruption technologies facilitate therapeutic agent delivery into the brain.
- These advancements allow for more precise identification of tumor infiltration and biological targeting.
Conclusions:
- Glioma surgery is evolving from an anatomy-guided to a biology-guided approach.
- Integrated use of optical theranostics and BBB disruption holds promise for improved glioma treatment.
- Future surgical strategies will leverage a deeper understanding of the glioma TME.
